Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J McLachlan

Showing results (1-10 of 327) with videos related to

Pageof 33
Sort By:
The Medical Journal of Australia|April 7, 2010
Generic medicines literacy - minimising the potential for patient confusionAndrew J McLachlan
The Medical Journal of Australia|June 19, 2008
Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: revised recommendationsAndrew J McLachlan,
Australian Prescriber|December 28, 2023
National Medicines Policy 2.0-what's changed and what's next?Andrew J McLachlan, Parisa Aslani
Australian Family Physician|April 4, 2013
Extrapulmonary tuberculosis--three cases in the spineAndrew J McLachlan, Revathy Arulventhan
Australian Prescriber|March 7, 2020
National Medicines Policy 2.0: a vision for the futureAndrew J McLachlan, Parisa Aslani
British Journal of Clinical Pharmacology|December 15, 2010
Clinical importance of the CYP2C19*17 variant allele for voriconazoleMichael J Dolton, Andrew J McLachlan
The Journal of Pharmacy and Pharmacology|February 19, 2002
In-vitro distribution of terbinafine in rat and human bloodMahboubeh Hosseini Yeganeh, Andrew J McLachlan
Antimicrobial Agents and Chemotherapy|May 16, 2013
Reply to "What types of Candida infections should be included when evaluating breakthrough infections during posaconazole prophylaxis?"Michael J Dolton, Andrew J McLachlan
Current Opinion in Infectious Diseases|September 18, 2014
Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infectionsMichael J Dolton, Andrew J McLachlan
Antimicrobial Agents and Chemotherapy|June 19, 2002
Physiologically based pharmacokinetic model for terbinafine in rats and humansMahboubeh Hosseini-Yeganeh, Andrew J McLachlan
Pageof 33

Showing results (1-10 of 327) with videos related to

Sort By:
Pageof 33
The Medical Journal of Australia|April 7, 2010
Generic medicines literacy - minimising the potential for patient confusionAndrew J McLachlan
The Medical Journal of Australia|June 19, 2008
Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: revised recommendationsAndrew J McLachlan,
Australian Prescriber|December 28, 2023
National Medicines Policy 2.0-what's changed and what's next?Andrew J McLachlan, Parisa Aslani
Australian Family Physician|April 4, 2013
Extrapulmonary tuberculosis--three cases in the spineAndrew J McLachlan, Revathy Arulventhan
Australian Prescriber|March 7, 2020
National Medicines Policy 2.0: a vision for the futureAndrew J McLachlan, Parisa Aslani
British Journal of Clinical Pharmacology|December 15, 2010
Clinical importance of the CYP2C19*17 variant allele for voriconazoleMichael J Dolton, Andrew J McLachlan
The Journal of Pharmacy and Pharmacology|February 19, 2002
In-vitro distribution of terbinafine in rat and human bloodMahboubeh Hosseini Yeganeh, Andrew J McLachlan
Antimicrobial Agents and Chemotherapy|May 16, 2013
Reply to "What types of Candida infections should be included when evaluating breakthrough infections during posaconazole prophylaxis?"Michael J Dolton, Andrew J McLachlan
Current Opinion in Infectious Diseases|September 18, 2014
Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infectionsMichael J Dolton, Andrew J McLachlan
Antimicrobial Agents and Chemotherapy|June 19, 2002
Physiologically based pharmacokinetic model for terbinafine in rats and humansMahboubeh Hosseini-Yeganeh, Andrew J McLachlan
Pageof 33